Haleon Plc: Preliminary 2024 Full Year Results Summary
Business Context and Reporting Period
Haleon Plc (LSE/NYSE: HLN), a global leader in consumer health, filed Form 6-K on February 27, 2025, announcing its preliminary full-year results for the period ended December 31, 2024. The company operates across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS).
Key Financial Metrics
The filing highlights strong free cash flow generation and organic profit growth during the year. Specific numerical values for revenue, net profit, cash flow, margins, debt, and liquidity are not provided in this summary text; investors are directed to the full preliminary results statement for detailed figures.
- Dividend Proposal: Total 2024 dividend of 6.6p per ordinary share.
- Payout Ratio: Approximately 37% of 2024 adjusted earnings (compared to 35% in 2023).
- Final Dividend: 4.6p per ordinary share.
Material Changes and Outlook
Management commentary emphasizes the strength of free cash flow and organic profit growth as drivers for the proposed dividend increase. The payout ratio increased by 2 percentage points year-over-year. No specific guidance for 2025 or detailed risk factors are included in this announcement text.
Investor Verification Checklist
- Verify the full preliminary results statement at the provided London Stock Exchange RNS link or Haleon investor website for detailed revenue and profit figures.
- Confirm the record date for the final dividend (April 25, 2025) and payment date (June 5, 2025).
- Review the Dividend Reinvestment Programme (DRIP) election deadline of May 15, 2025.
- Access the recorded results presentation and Q&A session on the Haleon investor website for management commentary on organic growth drivers.